Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POISE: Obeticholic Acid in Primary Biliary Cholangitis
NCT01473524Phase 3Completed
- Sponsor
- Intercept Pharmaceuticals
- Start
- Jan 2012
- Primary completion
- Dec 2013
- Modality
- Orthosteric Ligands
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of obeticholic acid in primary biliary cholangitis (PBC) (4 arms), sponsored by Intercept Pharmaceuticals. Primary endpoints: Composite Endpoint Alkaline Phosphatase (ALP) And Total Bilirubin at 12 months and Composite Endpoint ALP And Total Bilirubin (LTSE) at 60 months. Started Jan 2012; status: completed.
02
Drugs
obeticholic acid
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT01473524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01473524.